Cancer of the Prostate

Pipeline Programs↗

Active Trials↗

Companies Involved↗

Cancer of the Prostate is an early-stage landscape with 0 programs across 1 company. The most active players are Bayer.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

50/100

Attrition Rate

33/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Bayer

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

clinical trials

Withdrawn1 · 33%

Completed1 · 33%

Active, not recruiting1 · 33%

Clinical Trials

Trial Activity

Neoadjuvant Docetaxel on Newly Diagnosed Intermediate and High Grade Cancer of the Prostate

Withdrawn·—·Phase 2·NCT00598858

Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms

Completed· Bayer logo

Bayer·Phase 3·NCT02043678·806 enrolled

Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate

Active, not recruiting·UUniversity of Sydney·Phase 3·NCT04136353·1,100 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)